Sofia Skröder, Dritan Poci, Daniel Robert Smith, Mats Dreifaldt, Allan Sirsjö, Espen Fengsrud, Anna Björkenheim, Liza Ljungberg
{"title":"Bone morphogenetic protein 10 and one-year outcomes after open revascularisation in symptomatic peripheral arterial disease or carotid stenosis.","authors":"Sofia Skröder, Dritan Poci, Daniel Robert Smith, Mats Dreifaldt, Allan Sirsjö, Espen Fengsrud, Anna Björkenheim, Liza Ljungberg","doi":"10.1186/s12872-026-06568-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bone morphogenetic protein 10 (BMP10) has atrial-specific and vascular properties and may reflect both atrial and vascular pathophysiology. We investigated whether BMP10 levels were associated with new-onset atrial fibrillation (AF), major adverse cardiovascular events (MACE), and all-cause mortality after open revascularisation for symptomatic peripheral arterial disease (PAD) or carotid stenosis (CS).</p><p><strong>Methods: </strong>Patients scheduled for endarterectomy for symptomatic PAD or CS were enrolled. BMP10 concentrations were measured using a multiplex immunoassay. Clinical outcomes were obtained from medical records during one-year follow-up. Associations between BMP10 and outcomes were assessed using Cox proportional hazards regression.</p><p><strong>Results: </strong>A total of 210 patients were included (63% men; 61% underwent surgery for PAD). Women were older than men and had higher BMP10 levels. Forty patients had known preoperative AF. During one-year follow-up, 26 patients experienced MACE and 13 died. Among 170 patients without AF at baseline, 10 developed new-onset AF. In unadjusted Cox regression, higher BMP10 levels were associated with MACE (HR 1.01, 95% CI 1.00-1.03; p = 0.047) and all-cause mortality (HR 1.03, 95% CI 1.01-1.04; p < 0.001), but not with new-onset AF (HR 1.00, 95% CI 0.97-1.03; p = 0.80). Effect estimates were similar after adjustment for age and sex. Model-based point estimates of one-year cumulative incidence were numerically higher at higher BMP10 concentrations for MACE and all-cause mortality, although confidence intervals were wide; no corresponding pattern was observed for new-onset AF.</p><p><strong>Conclusions: </strong>In this exploratory cohort, higher BMP10 levels were associated with MACE and all-cause mortality after endarterectomy for symptomatic PAD or CS. Women had higher BMP10 levels than men. These findings should be interpreted cautiously and considered hypothesis-generating; larger studies are required to validate the observed associations.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13579758/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-026-06568-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Bone morphogenetic protein 10 (BMP10) has atrial-specific and vascular properties and may reflect both atrial and vascular pathophysiology. We investigated whether BMP10 levels were associated with new-onset atrial fibrillation (AF), major adverse cardiovascular events (MACE), and all-cause mortality after open revascularisation for symptomatic peripheral arterial disease (PAD) or carotid stenosis (CS).
Methods: Patients scheduled for endarterectomy for symptomatic PAD or CS were enrolled. BMP10 concentrations were measured using a multiplex immunoassay. Clinical outcomes were obtained from medical records during one-year follow-up. Associations between BMP10 and outcomes were assessed using Cox proportional hazards regression.
Results: A total of 210 patients were included (63% men; 61% underwent surgery for PAD). Women were older than men and had higher BMP10 levels. Forty patients had known preoperative AF. During one-year follow-up, 26 patients experienced MACE and 13 died. Among 170 patients without AF at baseline, 10 developed new-onset AF. In unadjusted Cox regression, higher BMP10 levels were associated with MACE (HR 1.01, 95% CI 1.00-1.03; p = 0.047) and all-cause mortality (HR 1.03, 95% CI 1.01-1.04; p < 0.001), but not with new-onset AF (HR 1.00, 95% CI 0.97-1.03; p = 0.80). Effect estimates were similar after adjustment for age and sex. Model-based point estimates of one-year cumulative incidence were numerically higher at higher BMP10 concentrations for MACE and all-cause mortality, although confidence intervals were wide; no corresponding pattern was observed for new-onset AF.
Conclusions: In this exploratory cohort, higher BMP10 levels were associated with MACE and all-cause mortality after endarterectomy for symptomatic PAD or CS. Women had higher BMP10 levels than men. These findings should be interpreted cautiously and considered hypothesis-generating; larger studies are required to validate the observed associations.
背景:骨形态发生蛋白10 (Bone morphogenetic protein 10, BMP10)具有心房特异性和血管特性,可能反映心房和血管病理生理。我们研究了BMP10水平是否与新发心房颤动(AF)、主要不良心血管事件(MACE)以及对症外周动脉疾病(PAD)或颈动脉狭窄(CS)开放性血运重建术后的全因死亡率相关。方法:纳入因症状性PAD或CS而计划行动脉内膜切除术的患者。采用多重免疫分析法测定BMP10浓度。临床结果来自一年随访期间的医疗记录。使用Cox比例风险回归评估BMP10与预后之间的关系。结果:共纳入210例患者(63%为男性,61%为PAD手术患者)。女性的年龄比男性大,BMP10水平也更高。术前已知房颤40例,随访1年,MACE 26例,死亡13例。在170例基线时无房颤的患者中,10例发生了新发房颤。未经校正的Cox回归分析显示,较高的BMP10水平与MACE (HR 1.01, 95% CI 1.00-1.03; p = 0.047)和全因死亡率(HR 1.03, 95% CI 1.01-1.04; p)相关。结论:在该探索性队列中,较高的BMP10水平与MACE和有症状的PAD或CS的动脉内膜切除术后的全因死亡率相关。女性的BMP10水平高于男性。这些发现应谨慎解释,并考虑到假设产生;需要更大规模的研究来验证观察到的关联。
期刊介绍:
BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.